VNDA - Vanda Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
931.53M
Enterprise Value 3
689.73M
Trailing P/E
7.86
Forward P/E 1
22.39
PEG Ratio (5 yr expected) 1
0.10
Price/Sales (ttm)
4.25
Price/Book (mrq)
2.32
Enterprise Value/Revenue 3
3.14
Enterprise Value/EBITDA 6
22.52

Trading Information

Stock Price History

Beta (3Y Monthly) 0.35
52-Week Change 3-40.32%
S&P500 52-Week Change 318.19%
52 Week High 331.30
52 Week Low 311.83
50-Day Moving Average 315.06
200-Day Moving Average 314.26

Share Statistics

Avg Vol (3 month) 3589.05k
Avg Vol (10 day) 3729.56k
Shares Outstanding 553.34M
Float 40.6M
% Held by Insiders 12.64%
% Held by Institutions 1102.58%
Shares Short (Nov 15, 2019) 43.84M
Short Ratio (Nov 15, 2019) 46.96
Short % of Float (Nov 15, 2019) 48.96%
Short % of Shares Outstanding (Nov 15, 2019) 47.20%
Shares Short (prior month Oct 15, 2019) 44.37M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 55.49%
Operating Margin (ttm)12.64%

Management Effectiveness

Return on Assets (ttm)4.41%
Return on Equity (ttm)36.75%

Income Statement

Revenue (ttm)219.3M
Revenue Per Share (ttm)4.14
Quarterly Revenue Growth (yoy)21.10%
Gross Profit (ttm)172.61M
EBITDA 30.63M
Net Income Avi to Common (ttm)121.7M
Diluted EPS (ttm)2.22
Quarterly Earnings Growth (yoy)1,300.40%

Balance Sheet

Total Cash (mrq)237.78M
Total Cash Per Share (mrq)4.46
Total Debt (mrq)14.92M
Total Debt/Equity (mrq)3.72
Current Ratio (mrq)4.67
Book Value Per Share (mrq)7.52

Cash Flow Statement

Operating Cash Flow (ttm)51.42M
Levered Free Cash Flow (ttm)39.61M